Literature DB >> 21584443

Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants.

E N Miyaji1, E Carvalho, M L S Oliveira, I Raw, P L Ho.   

Abstract

Aluminum salts have been widely used in vaccine formulations and, after their introduction more than 80 years ago, only few vaccine formulations using new adjuvants were developed in the last two decades. Recent advances in the understanding of how innate mechanisms influence the adaptive immunity opened up the possibility for the development of new adjuvants in a more rational design. The purpose of this review is to discuss the recent advances in this field regarding the attempts to determine the molecular basis and the general mechanisms underlying the development of new adjuvants, with particular emphasis on the activation of receptors of innate immune recognition. One can anticipate that the use of these novel adjuvants will also provide a window of opportunities for the development of new vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21584443     DOI: 10.1590/s0100-879x2011007500064

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  17 in total

1.  High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines.

Authors:  Ajay Grover; Jolynn Troudt; Chad Foster; Randall Basaraba; Angelo Izzo
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

2.  The expression of DAMP proteins HSP70 and cancer-testis antigen SPAG9 in peripheral blood of patients with HCC and lung cancer.

Authors:  Biqiong Ren; Shudi Luo; Fei Xu; Guoying Zou; Guofeng Xu; Junyu He; Yiran Huang; Haowen Zhu; Yong Li
Journal:  Cell Stress Chaperones       Date:  2016-12-27       Impact factor: 3.667

3.  Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice.

Authors:  Rafaella F Q Grenfell; Lisa M Shollenberger; E Farah Samli; Donald A Harn
Journal:  Clin Vaccine Immunol       Date:  2015-01-21

Review 4.  Cyclic di-nucleotides: new era for small molecules as adjuvants.

Authors:  Rimma Libanova; Pablo D Becker; Carlos A Guzmán
Journal:  Microb Biotechnol       Date:  2011-09-29       Impact factor: 5.813

Review 5.  Live bacterial vaccine vectors: an overview.

Authors:  Adilson José da Silva; Teresa Cristina Zangirolami; Maria Teresa Marques Novo-Mansur; Roberto de Campos Giordano; Elizabeth Angélica Leme Martins
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

Review 6.  Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.

Authors:  Huub F J Savelkoul; Valerie A Ferro; Marius M Strioga; Virgil E J C Schijns
Journal:  Vaccines (Basel)       Date:  2015-03-05

7.  Bacillus subtilis spores as vaccine adjuvants: further insights into the mechanisms of action.

Authors:  Renata Damásio de Souza; Milene Tavares Batista; Wilson Barros Luiz; Rafael Ciro Marques Cavalcante; Jaime Henrique Amorim; Raíza Sales Pereira Bizerra; Eduardo Gimenes Martins; Luís Carlos de Souza Ferreira
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

8.  Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice.

Authors:  Kyoung-Ho Pyo; You-Won Lee; Sun Min Lim; Eun-Hee Shin
Journal:  Oncotarget       Date:  2016-11-08

Review 9.  Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants.

Authors:  Kuang Tan; Ruizhen Li; Xiaotian Huang; Qiong Liu
Journal:  Front Microbiol       Date:  2018-04-26       Impact factor: 5.640

10.  Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection.

Authors:  María Belén Antonoglou; Andrés Sánchez Alberti; Daniela María Redolfi; Augusto Ernesto Bivona; María Julieta Fernández Lynch; Sofía Noli Truant; María Belén Sarratea; Laura Valeria Iannantuono López; Emilio Luis Malchiodi; Marisa Mariel Fernández
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.